Tango Therapeutics, Inc. (TNGX) Spending and interest coverage
- R&D / revenue · 12 months: Value 248.37%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 74.88%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 248.37% | Research and development expense / revenue. Period ending 2026-06-30. $133.65M ÷ $53.81M × 100 ≈ 248.37% |
| Stock-based compensation / revenue · 12 months | 74.88% | Share-based compensation / revenue. Period ending 2026-06-30. $40.29M ÷ $53.81M × 100 ≈ 74.88% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 133.65M USD | Research and Development Expense |
| Revenue | 53.81M USD | |
| Stock-based compensation | 40.29M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -136.35M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $133.65M | $53.81M | $40.29M | $-136.35M | (m) | 248.37% | 74.88% | (m) | (m) |
| 2026-03-31 | $129.26M | $56.99M | $29.97M | $-117.53M | (m) | 226.80% | 52.59% | (m) | (m) |
| 2025-12-31 | $132.16M | $62.38M | $26.43M | $-111.29M | (m) | 211.86% | 42.37% | (m) | (m) |
| 2025-09-30 | $134.00M | $66.50M | $27.91M | $-110.33M | (m) | 201.50% | 41.97% | (m) | (m) |
| 2025-06-30 | $136.45M | $24.30M | $28.46M | $-157.28M | (m) | 561.61% | 117.16% | (m) | (m) |
| 2025-03-31 | $142.29M | $40.99M | $29.43M | $-145.87M | (m) | 347.15% | 71.81% | (m) | (m) |
| 2024-12-31 | $143.92M | $42.07M | $28.90M | $-145.59M | (m) | 342.10% | 68.69% | (m) | (m) |
| 2024-09-30 | $141.32M | $43.38M | $26.31M | $-139.70M | (m) | 325.75% | 60.66% | (m) | (m) |
| 2024-06-30 | $135.21M | $42.51M | $24.00M | $-132.45M | (m) | 318.07% | 56.45% | (m) | (m) |
| 2024-03-31 | $125.22M | $37.23M | $21.58M | $-126.14M | (m) | 336.33% | 57.96% | (m) | (m) |
| 2023-12-31 | $115.20M | $36.53M | $19.08M | $-114.17M | (m) | 315.38% | 52.23% | (m) | (m) |
| 2023-09-30 | $112.95M | $37.51M | $17.98M | $-109.73M | (m) | 301.14% | 47.95% | (m) | (m) |
| 2023-06-30 | $114.55M | $33.70M | $16.94M | $-114.02M | (m) | 339.95% | 50.27% | (m) | (m) |
| 2023-03-31 | $109.61M | $24.87M | $15.24M | $-115.98M | (m) | 440.79% | 61.30% | (m) | (m) |
| 2022-12-31 | $105.91M | $24.86M | $14.23M | $-111.07M | (m) | 426.01% | 57.24% | (m) | (m) |
| 2022-09-30 | $98.45M | $24.16M | $12.70M | $-102.49M | (m) | 407.40% | 52.56% | (m) | (m) |
| 2022-06-30 | $91.63M | $24.03M | $12.32M | $-92.13M | (m) | 381.27% | 51.25% | (m) | (m) |
| 2022-03-31 | $86.97M | $36.41M | $10.09M | $-71.49M | (m) | 238.83% | 27.70% | (m) | (m) |
| 2021-12-31 | $77.64M | $37.04M | $7.83M | $-58.19M | (m) | 209.59% | 21.15% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |